Tesamorelin

Tesamorelin (brand name Egrifta) was developed by Theratechnologies and received FDA approval in 2010 for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy — a condition caused by antiretroviral therapy that causes abnormal fat redistribution, including visceral fat accumulation. It is the most clinically validated GH secretagogue available, with robust Phase 3 randomized controlled trial data confirming its efficacy and safety in human populations. As a GHRH analog with a stable C-terminally modified structure that resists degradation while retaining receptor binding activity, Tesamorelin stimulates pulsatile GH release with a pharmacokinetic profile better than natural GHRH (half-life ~26 minutes vs. seconds for endogenous GHRH). Tesamorelin's unique position in the GH peptide landscape is its combination of FDA approval (the highest evidentiary bar), substantial visceral fat reduction data in humans, and emerging evidence for cognitive benefits in aging populations from research conducted through the NIH.

Visceral adipose tissue reduction is Tesamorelin's most robustly documented effect. Phase 3 trials demonstrated mean reductions in visceral fat area of 15–18% over 26 weeks compared to placebo. This is clinically significant — visceral adiposity is independently associated with cardiovascular disease, insulin resistance, and metabolic syndrome. Selective visceral vs. subcutaneous fat targeting is a notable characteristic. Unlike many fat loss interventions that reduce total body fat relatively uniformly, Tesamorelin demonstrates preferential visceral fat reduction, which is the metabolically dangerous fat depot. Cognitive function improvement has emerged from National Institutes of Health-funded research examining Tesamorelin in older adults with mild cognitive impairment. Studies have shown improvements in executive function and verbal memory, consistent with GH's known role in brain function and the cognitive consequences of GH deficiency with aging. Metabolic neutrality — minimal effects on fasting glucose and insulin — distinguishes Tesamorelin from exogenous HGH, which typically worsens insulin sensitivity significantly at therapeutic doses.

Joint pain and arthralgia are the most commonly reported adverse effects in clinical trials, affecting approximately 15–20% of subjects. These are consistent with elevated GH levels and typically mild to moderate in severity. Fluid retention and edema occur in a similar proportion of patients, again consistent with GH elevation effects. Injection site reactions are common with daily SubQ injections — redness, pain, irritation, or lipoatrophy (fat loss at injection sites) from repeated injections in the same location. Site rotation is important. The effect reversal on discontinuation is a clinical reality — visceral fat reduction is not maintained after stopping Tesamorelin. This makes it effectively a chronic intervention for sustained results, with significant cost implications.

FDA-approved dose: 2 mg SubQ once daily at bedtime for the HIV lipodystrophy indication. Off-label use: 1–2 mg/day is used in research and off-label anti-aging contexts. Some practitioners use lower doses (1 mg/day) to reduce side effects while maintaining meaningful GH stimulation. Injection site: Abdomen, rotating sites to minimize local reactions. Monitoring: IGF-1 levels should be checked periodically to ensure values remain in an appropriate therapeutic range and do not become supraphysiological. Duration: The clinical trials that established efficacy ran for 26 weeks. Off-label use commonly follows similar 6-month periods with reassessment.

United States: FDA approved as Egrifta with a valid prescription for HIV lipodystrophy. Off-label prescribing is legal and practiced by physicians. Without a prescription, Tesamorelin is in the same research chemical gray zone as other GH peptides. Cost: Pharmaceutical-grade Egrifta is expensive — potentially thousands of dollars per month without insurance coverage. Insurance typically covers it only for HIV lipodystrophy indications. Compounded Tesamorelin from compounding pharmacies is available at lower cost. WADA: Prohibited as a GH secretagogue.

Tesamorelin's primary use is standalone for visceral fat reduction or as part of a comprehensive GH optimization protocol. Tesamorelin + Ipamorelin: Adding Ipamorelin provides ghrelin receptor pathway stimulation complementing Tesamorelin's GHRH pathway activity — a more comprehensive GH axis protocol. Tesamorelin + exercise: The trials showing visceral fat reduction used Tesamorelin with standard dietary and lifestyle maintenance. Exercise is not required for the visceral fat benefit but amplifies body composition outcomes.

Tesamorelin — Common Questions